{"id":"ist-atg-csa","safety":{"commonSideEffects":[{"rate":null,"effect":"Infection (bacterial, viral, fungal)"},{"rate":null,"effect":"Nephrotoxicity"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Neurotoxicity"},{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Thrombotic microangiopathy"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"ATG is a polyclonal antibody that depletes T lymphocytes, while cyclosporine A is a calcineurin inhibitor that blocks T-cell activation and cytokine production. Together, this combination provides potent immunosuppression through complementary mechanisms: ATG reduces the T-cell population while CsA inhibits the remaining T cells' proliferation and function. This dual approach is used to prevent graft-versus-host disease (GVHD) and improve engraftment in hematopoietic stem cell transplantation.","oneSentence":"IST combines anti-thymocyte globulin (ATG) and cyclosporine A (CsA) to suppress T-cell mediated immune responses and prevent graft rejection or autoimmune destruction.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:48:54.002Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of graft-versus-host disease in hematopoietic stem cell transplantation"},{"name":"Aplastic anemia treatment"}]},"trialDetails":[{"nctId":"NCT05600426","phase":"PHASE3","title":"A Trial Comparing Unrelated Donor BMT With IST for Pediatric and Young Adult Patients With Severe Aplastic Anemia (TransIT, BMT CTN 2202)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Boston Children's Hospital","startDate":"2023-01-25","conditions":"Severe Aplastic Anemia","enrollment":53},{"nctId":"NCT07338422","phase":"NA","title":"HID-HSCT Versus IST as First-line Treatment for SAA","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-01-14","conditions":"Aplastic Anaemia","enrollment":116},{"nctId":"NCT07001254","phase":"PHASE2","title":"UI-Romi-02; Romiplostim Added to Standard of Care for Treatment Naive and Relapsed or Refractory Severe Aplastic Anemia","status":"NOT_YET_RECRUITING","sponsor":"Anjali Sharathkumar","startDate":"2026-08-01","conditions":"Aplastic Anemia","enrollment":15},{"nctId":"NCT06430788","phase":"PHASE2","title":"A Study of Emapalumab for Pediatric Aplastic Anemia","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2024-05-21","conditions":"Aplastic Anemia, Cytopenia, Hypocellular Marrow","enrollment":35},{"nctId":"NCT07010237","phase":"PHASE2","title":"Dose-attenuated IST and Hetrombopag in Elderly (≥65 Years) Patients With Severe Aplastic Anemia","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-02-01","conditions":"Sever Aplastic Anaemia, Elderly (People Aged 65 or More), Immunosuppressive Treatment","enrollment":65},{"nctId":"NCT02845596","phase":"NA","title":"Unrelated Donor Transplant Versus Immune Therapy in Pediatric Severe Aplastic Anemia","status":"COMPLETED","sponsor":"Michael Pulsipher","startDate":"2016-08","conditions":"Severe Aplastic Anemia","enrollment":40},{"nctId":"NCT05323617","phase":"PHASE2","title":"Efficacy of Romiplostim in Treatment of SAA in Adults Previously Untreated With or Refractory to Immunosuppressive Therapy","status":"WITHDRAWN","sponsor":"Amgen","startDate":"2023-08-31","conditions":"Severe Aplastic Anemia (SAA)","enrollment":""},{"nctId":"NCT06009965","phase":"PHASE4","title":"Efficacy of IST Combined With TPO-RA in the Treatment of AA and Establishment of a Recurrence Prediction System","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2023-01-20","conditions":"Aplastic Anemia, CSA, Drug Therapy","enrollment":210},{"nctId":"NCT02745717","phase":"PHASE4","title":"The Efficacy of Immunosuppressive Therapy Combined With Cord Blood Transfusion in Treatment of Severe Aplastic Anemia","status":"COMPLETED","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2016-01","conditions":"Severe Aplastic Anemia","enrollment":60},{"nctId":"NCT05571332","phase":"NA","title":"Efficacy and Safety of Avatrombopag Combined With IST for the Treatment of HAAA and SAA With Abnormal Liver Function","status":"UNKNOWN","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2022-06-28","conditions":"Aplastic Anemia","enrollment":39},{"nctId":"NCT03413306","phase":"PHASE3","title":"Eltrombopag+hATG+CsA vs. hATG+CsA in Children With Severe AA","status":"UNKNOWN","sponsor":"Federal Research Institute of Pediatric Hematology, Oncology and Immunology","startDate":"2016-12-10","conditions":"Acquired Aplastic Anemia","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":19,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["controle"],"phase":"phase_3","status":"active","brandName":"IST (ATG + CsA)","genericName":"IST (ATG + CsA)","companyName":"Federal Research Institute of Pediatric Hematology, Oncology and Immunology","companyId":"federal-research-institute-of-pediatric-hematology-oncology-and-immunology","modality":"Small molecule","firstApprovalDate":"","aiSummary":"IST (ATG + CsA) is a treatment modality used for conditions such as Acquired Aplastic Anemia and Aplastic Anemia, which involves the use of a protein-based intervention. The treatment combines the use of ATG (Antithymocyte globulin) and CsA (Cyclosporine), which are administered together to manage these conditions.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}